An Advanced Decision Support Tool, Opt-IVF for Clinical Ivf Practice
Study Details
Study Description
Brief Summary
Aim: A Clinical trial to determine the effectiveness of using the proposed decision support tool for each patient's customized optimal drug dosage profile. This will be a two-arm clinical trial involving 200 patients; one arm will undergo superovulation using dosages predicted by the decision support tool while the other arm will undergo current standard treatment. The investigators will compare the outcomes of the two groups of patients in terms of the numbers and percentage of mature follicles retrieved at the end of each cycle, total FSH and HMG dosages used, and the number of required testing days for that cycle. The patients considered will include all ages, with and without PCOS, and low, average, and high responders.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Objectives/Aims
Aim: A Clinical trial to determine the effectiveness of using the proposed decision support tool for each patient's customized optimal drug dosage profile.
Subject Enrollment
The recruitment plan designed is study-specific and site-specific. The investigators plan to recruit patients by reaching into the center's own database of patients. This center carries out on average 800 IVF cycles per year. PIs anticipate easier recruitment since they are not excluding any IVF patients, whether they are low, high, or average responders undergoing any protocol or patients with PCOS or not. The in-reach activities to be used include:
-
Chart review from site patient database
-
Establishing an internal referral network with all physicians within the site
-
Educational meetings with providers and physicians
-
Educational sessions with patients and relatives
-
Financial assistance to patients undergoing the intervention
-
Training staff to facilitate ICF process by o Effectively conveying risks and benefits
-
Creating an open environment
-
Monthly calls to site physicians and staff to convey success stories
The retention activities include:
-
Planning appointments with sites for initial/follow-up visits and providing flexible/convenient appointment times
-
Spending extra time with patients to understand their concerns and address them effectively
-
Providing a summary of laboratory results to patients to demonstrate progress
-
Appointment reminder services
-
Travel assistance for patients/family members/caregivers, and patient compensation services
-
Identifying the warning signals for potential drop-outs and working closely with these patients to support them to continue on the study
Study Design and Procedures
This is a single-site cohort with two arms (one arm for the intervention and one arm for the traditional approach) clinical trial involving 200 patients.
The main site for this task is the Akansha Hospital, and all the analysis will be carried out at the Stochastic Research site. Dr. Urmila Diwekar will be an investigator from the Stochastic Research Technologies LLC, and Dr. Patel will be an investigator from the Akansha Hospital. Apart from these two investigators, there will be a post-doctoral fellow from Stochastic Research Technologies LLC and medical personnel from the Akanksha Hospital other than Dr. Patel will be involved in this proposed clinical trial.
In our study, Opt-IVF will be using the patient's age and day three serum day AMH and AFc levels to decide the starting dose for the patient's cycle. Opt-IVF will use the first day and day 5 data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool OPTIVF for this intervention in the clinical trial.
Primary and secondary outcomes: The study's primary outcome measures will be: the proportion of women with an appropriate number of retrieved oocytes), total hormonal dosage employed during the cycle, and serum oestradiol concentrations on rHCG day, no.of ultrasounds, no. of M2s, no. of embryos obtained, no. of grade A embryos.
The secondary outcome measures considered will be: the number of growing follicles (≥11 mm) on rHCG day; the number of large ovarian follicles ≥17 mm on rHCG day embryos transferred, fertilization rate, implantation rate, clinical pregnancy rate, OHSS rate, the number of cryopreserved embryos and the proportion of patients with cryopreserved embryos.
Data sources
Data Sources will be View Point (GE) and Syngo Dynamics (Phillips) for the sonographic images and Cerner for medical record information.
Expected Risks/Benefits
Current practice is to use every ultrasound and blood test every day to determine the dosage for that day that patient by the attending physician. The proposed decision support tool will be able to predict the patient's response to the hormonal dosage given each day of an IVF cycle using data from the first two days of that particular cycle. It will also provide a personalized optimal dosage profile for each patient, maximizing the outcomes and reducing medications, testing, and side effects. Based on earlier preliminary results, the tool use is expected to reduce the daily testing up to 75%, reduce the dosage up to 40%, thereby reducing the side effects like overstimulation, and is expected to provide equal or better outcomes for the patients. Dr. Diweakr's group have carried out retrospective studies with 150 patients in the USA and India. The investigators also carried out a small prospective clinical trial in India. Both studies support the above conclusion about the methodology. In this study, the investigators will be conducting prospective clinical studies for this product in the United States. This will establish the efficacy of this tool for use in clinical practice. There is no additional risk with the use of this decision support tool other than the possibility of an unsuccessful cycle, a risk that exists with current practice also. The same medications are used at dosages 20-40% lower, thus reducing the side effects of the medications.
Data Collection and Management Procedures
-
Collecting the de-identified patient data without any PHI. All the information will be digitized and managed securely (as needed), so it can be analyzed and researched. Proprietary file formats may be used in this process.
-
Data Protection Throughout the research work of this project, a large volume of data at various levels of detail. All research members will adhere to the highest standards for protecting subjects' privacy and the confidentiality of any information collected. Only properly trained and authorized individuals may access data with personal identifiers at the University of Chicago IVF center. Nobody from stochastic research technologies will have access to personal identifiers.
-
Backups The company provide automated computer backups.
-
Web Server It has been planned to disseminate and maintain project information through Stochastic webservers. These are all hosted on a Windows Server, a VMware virtual machine instance.
Data Analysis Data analysis will be performed by the co-PI using SPSS software.
Quality Control and Quality Assurance Data is recorded and coded in an electronic database. Categorical data will be compared using Chi-square or Fischer exact test and ANOVA for frequency table of baseline characteristics. Odds ratios and 95% confidence intervals will be calculated, as well as 2-sided p values. A value less than 0.05 will be chosen for significance without adjustment for multiple comparisons. A biostatistician will be consulted for any statistical analysis beyond the scope of the PI or co-investigators.
1 Data and Safety Monitoring De-identified data collected is in an excel spreadsheet in a password-protected computer.
Statistical Considerations Sample size: Earlier clinical trial shows that for obtaining statistically significant outcomes for comparing dosage and grade A embryos a small sample 22 patients in each arm was sufficient. However, for other outcomes like number of M2s higher samples size may be needed. Based on earlier results, the number of samples size is calculated to be 80 patients in each arm. Therefore, a sample size of 100 in each arm will be used in this trial.
Analysis Methods: Between the groups, differences in continuous variables will be assessed with parametric or non-parametric statistics, as appropriate. Z-tests will be conducted comparing the proportion of individuals who reported an optimal outcome response.
Regulatory Requirements Informed Consent The OPTIVF trial will be registered with Clinical Trials.Gov as per ACTG guidelines. PIs have established IRB-approved consent forms. This consent form is based on regular or long-form. The form presents detailed information about the treatments, risks, and benefits, mitigation of risks, etc., in summary, complete details on all elements of consent. Dr. Patel is responsible for this. The signed consent forms hard copy data will be securely stored in a locking cabinet in the Akanksha hospital office.
Subject Confidentiality The confidentiality of participants will be safeguarded by the use of a de-identified dataset. A master data spreadsheet including any necessary PHI will be kept in a locked file on a secure drive. All data analysis will be performed on the de-identified dataset. The key for the identification will be kept in a third locked file separate from the data. Only the co-PI will have access to these files. Data will be entered into SPSS or other statistical software programs for analysis without subject identifiers.
Unanticipated Problems Any unanticipated problems will be reported to the IRB as soon as they are discovered.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Opt-IVF predicted drug dosage In this arm, OPT-IVF will use the patient's age and day three serum day AMH and AFC levels to decide the starting dose for the patient's cycle. It will also use the first day and day 5 data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient. The dosage predicted by Opt-IVF will be used for the patient in this arm. |
Other: Opt-IVF predicted dosage
The patients in this arm will be given dosage predicted by Opt-IVF.
|
| Active Comparator: Traditional drug treatment The current practice of Physician specified dosage will be used in this arm. |
Other: traditional drug treatment
The patients in this arm will be given doctor specified dosage.
|
Outcome Measures
Primary Outcome Measures
- Total per cycle dosage [At the end of cycle 1 (each cycle is 17 days)]
Average dosage per cycle
- Number of Ultrasounds [At the end of cycle 1 (each cycle is 17 days)]
average number of ultrasounds per cycle
- Number of mature oocytes retrieved [At the end of cycle 1 (each cycle is 17 days)]
average oocytes retrieved
- Number of Metaphase 2 follicles [At the end of cycle 1 (each cycle is 17 days)]
average number of M2s obtained per cycle
- Number of Embryos [At the end of cycle 1 (each cycle is 17 days)]
average number of Embryos per cycle
- Number of Grade A embryos [At the end of cycle 1 (each cycle is 17 days)]
average number of grade A embryos per cycle
Secondary Outcome Measures
- Pregnancy rate [0-3 months]
Average rate of pregnancy
Eligibility Criteria
Criteria
Inclusion Criteria:
- women between 18 to 50 years of age
Exclusion Criteria:
- men and children
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Akansha Hospital and Research Institute | Anand | Gujrat | India | 388001 |
Sponsors and Collaborators
- Stochastic Research Technologies LLC
- Akansha Hospital and Research Institute, India
Investigators
- Principal Investigator: Urmila Diwekar, Stochastic Research Technologies LLC
Study Documents (Full-Text)
None provided.More Information
Publications
- Diwekar U, Patel N, Patel N, Patel M, Bhadarka H, Ghoghari P, et al.(2022). A Non-Randomized Clinical Trial of a Decision Support Tool to Optimize Superovulation Cycles in Individual Patients. J Fertil In vitro IVF World w Reprod Med Genet Stem Cell Biol. 10:261.
- Nisal A, Diwekar U, Hobeika E. Personalized medicine for GnRH antagonist protocol in in vitro fertilization procedure using modeling and optimal control. Comput Chem Eng. 2022;156:107554.
- Yenkie KM, Diwekar U. Uncertainty in clinical data and stochastic model for in vitro fertilization. J Theor Biol. 2015 Feb 21;367:76-85. doi: 10.1016/j.jtbi.2014.11.004. Epub 2014 Dec 4.
- SRT-2022-2